title: Pressure-mediated vasoconstriction of juxtamedullary afferent arterioles involves P2-purinoceptor activation.
abstract: This study was conducted to examine the hypothesis that P2 purinoceptors contribute to pressure-induced autoregulatory adjustments of afferent arteriolar caliber. Experiments were performed in vitro using the blood-perfused juxtamedullary nephron technique. Afferent arteriolar diameter averaged 19.2 +/- 0.6 microns (n = 51) at control perfusion pressure of 100 mmHg and decreased when perfusion pressure was increased. Desensitization of P2 purinoceptors abolished the alpha, beta-methylene ATP-mediated afferent vasoconstriction and prevented pressure-dependent autoregulatory adjustments in afferent diameter. P2-purinoceptor saturation significantly decreased afferent caliber and attenuated pressure-induced autoregulatory responses. To block P2 receptors, afferent arterioles were treated with the P2-purinoceptor antagonists, pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid or suramin. P2-receptor blockade prevented the afferent arteriolar vasoconstriction evoked by increasing perfusion pressure from 100 to 130 and 160 mmHg. These data demonstrate that inhibition of P2 purinoceptor-dependent responses through receptor desensitization, receptor saturation, or purinoceptor blockade impairs normal autoregulatory behavior in rat juxtamedullary afferent arterioles. The results are consistent with the hypothesis that P2 purinoceptors participate in mediating autoregulatory adjustments in afferent arteriolar diameter.
authors.affiliation: Department of Physiology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
authors.forename: E W
authors.initials: EW
authors.lastname: Inscho
authors.forename: A K
authors.initials: AK
authors.lastname: Cook
authors.forename: L G
authors.initials: LG
authors.lastname: Navar
mesh_terms: D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001160:Arterioles / Q000502:physiology; D006706:Homeostasis; D006801:Humans; D007679:Kidney Medulla / Q000098:blood supply*; D008297:Male; D010477:Perfusion; D011312:Pressure; D058914:Purinergic Antagonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011983:Receptors, Purinergic / Q000502:physiology*; D012079:Renal Circulation / Q000187:drug effects / Q000502:physiology; D013498:Suramin / Q000494:pharmacology; D013997:Time Factors; D014661:Vasoconstriction
chemical_list: D058914:Purinergic Antagonists; D011983:Receptors, Purinergic; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D013498:Suramin; D000255:Adenosine Triphosphate; C002630:alpha,beta-methyleneadenosine 5'-triphosphate